China
Intelligence de marché des dispositifs médicaux pour China. Changements réglementaires, concurrents et tendances d'achats.
Table pays dernière MAJ : 9 août 2026 (peut être en retard). Le total 7 j est recalculé en direct (ancienne valeur table : 341).
Signaux des 7 derniers jours
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease - OncLive
Harbour BioMed Receives China NMPA Approval Of Batoclimab Injection (Subcutaneous Injection) For The Treatment Of Generalized Myasthenia Gravis - www.marketscreener.com
HanAll Biopharma wins China approval for myasthenia gravis drug batoclimab - CHOSUNBIZ - Chosunbiz
Harbour BioMed's batoclimab wins China gMG approval amid HanAll licensing dispute - AllSci
Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis - Newport Daily Express